Medtronic receives fda approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest

First-of-its-kind aurora ev-icd™ system offers single device, single procedure with lead placed outside of heart and veins dublin , oct. 23, 2023 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, has received u.s. food and drug administration (fda) approval for the aurora ev-icd™ mri surescan™ (extravascular implantable cardioverter-defibrillator) and epsila ev™ mri surescan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest (sca). the aurora ev-icd system is the first-of-its-kind to provide the life-saving benefits of traditional, transvenous icds with a lead (thin wire) placed under the breastbone, outside of the heart and veins.
MDT Ratings Summary
MDT Quant Ranking